Would you still obtain Ki-67 prior to use of adjuvant abemaciclib in a patient who has otherwise met MonarchE treatment criteria, such as 1-3 positive LNs, grade 3 and/or tumor >5 cm?
Patient is pre-menopausal and has cT3cN1, grade 2, ER positive, Her 2 negative IDC. Metastatic disease to axillary LNs was biopsy-proven. Patient was given neoadjuvant ddAC-T with excellent response (ypT1cN0(i+)) post-lumpectomy. Would their response to neoadjuvant chemotherapy affect your decision?
Community PollStarted
Would you obtain Ki-67 prior to adjuvant abemaciclib in a patient who has otherwise met MonarchE treatment criteria?
46 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Pittsburgh School of Medicine
Answered on
In the setting of a patient with residual disease after NAT with an initial grade 3 stage IIIA ER positive breast cancer, I would treat with adjuvant abemaciclib regardless of Ki67 status if the absolute risk of recurrence was high enough. pCR rates after NAT for ER positive breast cancer are low, a...
Join for free or sign in to see the full answer